Skip to main content

Advertisement

Table 4 Drug resistance interpretation for the three superinfection cases

From: Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

Regime Case13 Case14 DBC+
  Resident strain Superinfecting strain Resident strain Superinfecting strain Resident strain Superinfecting strain
3TC HR HR PL S S HR
ABC HR LL R S S HR
ATV/r S LL S S S S
AZT HR R HR LL PL HR
D4T HR R HR PL LL HR
DDI HR PL R S PL HR
DLV S S S S S S
DRV/r S S S S S S
EFV S S S S S S
ETR S S S S S S
EVG S S S S S S
FPV/r S LL S S S S
FTC HR HR PL S S HR
IDV/r S R S S S S
LPV/r S PL S S S S
NFV S HR S S S S
NVP S S S S S S
RAL S S S S S S
SQV/r S R S S S S
TDF R PL R S PL LL
TPV/r S S S S S S
  1. Drug resistance (based on http://hivdb.stanford.edu) in the two patients with validated superinfection and the patient suspected for superinfection based on high degenerate base code (DBC) count. Drug resistance interpretation is shown for the samples preceding and following the suspected superinfection event; bullets indicate the drugs administered in the sample interval. In Case 13, resistance against two of the drugs decreased, while resistance against one drug increased concomitant with superinfection; in Case 14, resistance against the current drugs decreased; in the DBC+ case, resistance against both drugs increased. None of the cases involved currently recommended drug regimens. S: Susceptible, PL: Potential low-level resistance, LL: low-level resistance, R: resistance, HR: high resistance.